Activated factor XI-antithrombin complex presenting as an independent predictor of 30-days mortality in out-of-hospital cardiac arrest patients

Reidun Aarsetøy*, Hugo Ten Cate, Henri Spronk, Rene Van Oerle, Hildegunn Aarsetøy, Harold Staines, Dennis W T Nilsen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Cardiac arrest and cardiopulmonary resuscitation (CPR) are associated with activated coagulation and microvascular fibrin deposition with subsequent multiorgan failure and adverse outcome.

OBJECTIVES: Activated Factor XI-antithrombin (FXIa-AT) complex, activated Factor IX-antithrombin (FIXa-AT) complex and thrombin-antithrombin (TAT) complex were measured as markers of coagulation activation, and evaluated as independent prognostic indicators in out-of-hospital cardiac arrest (OHCA) patients.

METHODS: From February 2007 until December 2010 blood samples were collected in close approximation to CPR from patients with OHCA of assumed cardiac origin. Follow-up samples in survivors were drawn 8-12 h and 24-48 h after hospital admission. All measurements were determined by ELISA.

RESULTS: Thirty-seven patients presented with asystole and 77 with ventricular fibrillation as first recorded heart rhythm. At 30-days follow-up, 70 patients (61.4%) had died. All patients had elevated levels of FXIa-AT complex, FIXa-AT complex and TAT. Initial levels were significantly higher in non-survivors compared to 30-days survivors. A significant increase in risk of 30-days all-cause mortality was observed through increasing quartiles of all three biomarkers in univariate Cox regression analysis. Compared to the lowest quartile (Q1), only FXIa-AT complex levels in Q3 (HR 3.17, p = 0.011) and Q2 (HR 3.02, p = 0.016) were independently associated with all-cause mortality in the multivariable analysis. FIXa-AT complex and TAT-complex did not behave as independent predictors.

CONCLUSIONS: Complexes of FXIa-AT were independently associated with 30-days survival in OHCA-patients.

CLINICAL TRIAL REGISTRATION: ClinicalTrials. gov, NCT02886273.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalThrombosis Research
Volume204
Early online date29 May 2021
DOIs
Publication statusPublished - Aug 2021

Keywords

  • AMERICAN-HEART-ASSOCIATION
  • CARDIOPULMONARY
  • COAGULATION-FACTOR XI
  • COAGULOPATHY
  • Coagulation activation
  • Factor IXa-antithrombin complex
  • Factor XIa-antithrombin complex
  • INHIBITION
  • INTERNATIONAL LIAISON COMMITTEE
  • Out-of-hospital cardiac arrest
  • Prognosis
  • RESUSCITATION
  • RISK
  • STATEMENT
  • SURVIVAL
  • Thrombin-antithrombin complex

Cite this